Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Tyra Biosciences, Inc.NASDAQ: TYRA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$39.31M, compared with -$28.15M a year earlier. Trailing-twelve-month net income was -$131.11M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$150.91M (-25.8%) for the fiscal year ending Dec 2026, a step up from the -38.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.31M-16.2% QoQ
- Last fiscal yearDec 2025
- -$119.95M-38.7% YoY
- LTMMar 2026
- -$131.11M-36.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -39.6% | -42.5% | -2.8 pp |
| 1 year | -38.7% | -25.8% | +12.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (119.95M) USD
- Year-over-year change
- -38.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (119.95M) | -38.7% |
| FY2024 | 2024-12-31 | (86.48M) | -25.1% |
| FY2023 | 2023-12-31 | (69.13M) | -25.0% |
| FY2022 | 2022-12-31 | (55.33M) | -110.4% |
| FY2021 | 2021-12-31 | (26.29M) | — |
Net Income vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 net income of -$131.11M is the 4th highest of the 11 companies compared; the peer median is -$147.53M.
- Its year-over-year change of -36.0% is the 8th highest of 11, against a peer median of -24.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$70.36M | -26.1% | — | 44.8% | |
| LTM Mar 2026 | -$75.32M | +6.4% | — | 266.9% | |
| LTM Mar 2026 | -$114.48M | -47.3% | — | 529.7% | |
| LTM Mar 2026 | -$131.11M | -36.0% | — | — | |
| LTM Mar 2026 | -$135.21M | -1.8% | — | — | |
| LTM Mar 2026 | -$145.24M | -14.0% | — | — | |
| LTM Jun 2026 | -$149.83M | +26.2% | — | 88.2% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | -$157.32M | -70.4% | — | — |
| LTM Mar 2026 | -$193.96M | -30.3% | — | 391.2% | |
| LTM Mar 2026 | -$221.04M | -23.7% | — | — | |
| LTM Mar 2026 | -$294.57M | -62.0% | — | 411.2% | |
| Peer median (excluding TYRA) | -$147.53M | -24.9% | — | 329.0% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Selling, General & Admin | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| Operating Expenses | 26.29M | 58.93M | 79.95M | 104.18M | 132.76M |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| EBITDA | (26.15M) | (55.03M) | (68.78M) | (85.96M) | (119.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (26.29M) | (58.93M) | (79.95M) | (104.18M) | (132.76M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 3.65M | 10.81M | 17.7M | 12.82M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6K) | 3.6M | 10.81M | 17.7M | 12.82M |
| Income Before Tax | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| EPS (Diluted) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| Weighted Avg Shares | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Weighted Avg Shares (Diluted) | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.